CCL2 and breast carcinoma: Ca-TAT/siRNA complexes were observed to efficiently transfect MDA-MB-231 and DCIS.com breast cancer cells plated in 2D and 3D cultures, and reduce CCL2 expression more effectively than CCL2 neutralizing antibodies.